Marco Ruella, MD
Associate Professor of Medicine (Hematology-Oncology)
Project Member, Parker Institute for Cancer Immunotherapy
Attending, Hospital of the University of Pennsylvania
Leader, Cancer Research, Institute for Immunology
Scientific Director, Lymphoma Program, Division of Hematology and Oncology
Full Member, Abramson Cancer Center, Immunobiology Program
Scientific Director, Richard Berman Center for Innovations in CLL and lymphomas
Medical Director , Cellular Therapies, Penn Global Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Office: 215-746-4880
Fax: 215-573-3638
Lab: 215-573-8538
Fax: 215-573-3638
Lab: 215-573-8538
Email:
mruella@upenn.edu
mruella@upenn.edu
Publications
Links
Search PubMed for articles
Twitter
LinkedIn
Google Scholar
Institute for Immunology
Academia.edu
Research Gate
Ruella Lab Website
Search PubMed for articles
Google Scholar
Institute for Immunology
Academia.edu
Research Gate
Ruella Lab Website
Education:
MD (Medical Degree)
University of Torino, Italy , 2007.
Permanent linkMD (Medical Degree)
University of Torino, Italy , 2007.
Description of Clinical Expertise
Dr. Ruella treat patients affected by hematological cancers and specializes in immunotherapy approaches.Description of Research Expertise
Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), and the Leukemia and Lymphoma Society, Translational Research Program (2021). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.
Selected Publications
Luciani F, Safavi A, Guruprasad P, Chen L, Ruella M.: Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges. Blood Cancer Discov. 6(3): 159-162, May 2025 Notes: doi: 10.1158/2643-3230.BCD-23-0240.Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH.: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med 392: 1824-1835, May 2025.
Fiore D, Cappelli LV, Zhaoqi L, Kotlov N, Sorokina M, Phillip J, Zumbo P, Yoffe L, Ghione P, Wang A, Han X, Taylor A, Chiu W, Fragliasso V, Tabbo F, Zamponi N, Di Siervi N, Kayembe C, Medico G, Patel RP, Gaudiano M, Machiorlatti R, Astone G, Cacciapuoti MT, Zanetti G, Pignataro C, Eric RA, Patel S, Zammarchi F, Zanettini C, Queiroz L, Nikitina A, Kudryashova O, Karelin A, Nikitin D, Tychinin D, Postovalova E, Bagaev A, Svekolkin V, Belova E, Tikhonova K, Degryse S, Xu C, Novero D, Ponzoni M, Tiacci E, Falini B, Song J, Khodos I, De Stanchina E, Macari G, Cafforio L, Gardini S, Piva R, Medico E, Ng SY, Moskowitz A, Epstein Z, Intlekofer A, Ahmed D, Chan WC, Martin P, Ruan J, Bertoni F, Foà R, Brody JD, Weinstock DM, Osan J, Santambrogio L, Elemento O, Betel D, Tam W, Ruella M, Cerchietti L, Rabadan R, Horwitz S, Inghirami G.: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. Cell Rep Med. 6(4), April 2025 Notes: doi: 10.1016/j.xcrm.2025.102029.
Myers RM, DiNofia AM, Li Y, Diorio C, Liu H, Wertheim G, Fraietta JA, Gonzalez V, Plesa G, Siegel DL, Iannone E, Shinehouse L, Brogdon JL, Taylor C, Jadlowsky JK, Hexner EO, Engels B, Baniewicz D, Callahan C, Ruella M, Aplenc R, Barz Leahy A, McClory SE, Rheingold SR, Wray L, June CH, Maude SL, Frey NV, Grupp SA.: CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. J Immunother Cancer. 13(4), April 2025 Notes: doi: 10.1136/jitc-2025-011549.
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med Page: 1134-1144, April 2025.
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP, Tan M, Padmanabhan AA, Lemoine J, Fardella E, Zhang Y, Pajarillo R, Chen L, Ugwuanyi O, Markowitz K, Delman D, Angelos MG, Shestova O, Isshiki Y, Blanchard T, Béguelin W, Melnick AM, Linette GP, Beatty GL, Carreno BM, Cohen IJ, Paruzzo L, Schuster SJ, Ruella M.: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell 43: 537-551, Mar 2025.
Monette A, Aguilar-Mahecha A, Altinmakas E, Angelos MG, Assad N, Batist G, Bommareddy PK, Bonilla DL, Borchers CH, Church SE, Ciliberto G, Cogdill AP, Fattore L, Hacohen N, Haris M, Lacasse V, Lie WR, Mehta A, Ruella M, Sater HA, Spatz A, Taouli B, Tarhoni I, Gonzalez-Kozlova E, Tirosh I, Wang X, Gnjatic S. : The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application. Clin Cancer Res. 31(3): 439-456, Feb 2025 Notes: doi: 10.1158/1078-0432.CCR-24-2469.
Ghilardi G, Hasanali ZS, Susanibar-Adaniya SP, Winestone LE, Ruella M, Garfall AL.: Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review. J Immunother Cancer. 13(1), Jan 2025 Notes: doi: 10.1136/jitc-2024-009349.
Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno TC, Carturan A, Hammer C, Ho WS, Kather JN, Kirchhoff T, Lu RO, McQuade J, Najjar YG, Pietrobon V, Ruella M, Shen R, Soldati L, Spencer C, Betof Warner A, Warren S, Ziv E, Marincola FM.: Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review. J Immunother Cancer. 13(1), Jan 2025 Notes: doi: 10.1136/jitc-2024-008876.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J, Easwar Kumar V, Carrasco SE, Ouseph MM, Yamshon S, Martin P, Griess O, Shema E, Porazzi P, Ruella M, Brentjens RJ, Inghirami G, Zappasodi R, Chadburn A, Melnick AM, Béguelin W.: EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell 43: 49-68, Jan 2025.